Filing summary
Outlook Therapeutics, Inc. reported that on September 25, 2026, Nasdaq notified it that its common stock had closed below the $1.00 minimum bid price for 30 consecutive business days. The company signed the 8-K on September 30, 2026.
Financial and operating information
The filing provides no revenue, profit, cash flow, margin, debt, or liquidity figures. It reports a minimum bid price requirement of $1.00 per share; the stock’s specific closing price is not stated.
Listing status and outlook
The notice has no immediate effect on the stock’s Nasdaq Capital Market listing. Outlook Therapeutics has until March 24, 2027 to regain compliance by closing at or above $1.00 for at least 10 consecutive business days.
If the company does not meet the requirement by that date, it may qualify for an additional 180-day compliance period, subject to other listing requirements and notifying Nasdaq of its intent to cure the deficiency, potentially through a reverse stock split. Otherwise, Nasdaq may issue a delisting determination. The company may appeal, but success is not assured.
The company said it will monitor the bid price and evaluate options to resolve the deficiency. The filing does not specify which corrective action, if any, it will take.
Key facts to verify
- Whether the stock regains the $1.00 minimum bid price for the required 10 consecutive business days by March 24, 2027.
- Whether the company qualifies for and seeks the additional compliance period, including any reverse stock split.
- Any subsequent Nasdaq notice, delisting determination, or appeal outcome.